Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184278 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1ALDH1A1PLA2G2CFOLH1 | |
| SCHEMBL13019264 | 0.85 | PLA2G2C (0.44) | TAS1R3TAS1R1ALDH1A1PLA2G2C | |
| SCHEMBL3176866 | 0.84 | ALDH1A1 (0.61) | ALDH1A1PLA2G2CFOLH1 | |
| SCHEMBL3176868 | 0.84 | ALDH1A1 (0.61) | ALDH1A1PLA2G2CFOLH1 | |
| SCHEMBL3182926 | 0.83 | TAS1R3 (0.40) | TAS1R3TAS1R1FOLH1BIRC2 | |
| SCHEMBL3182911 | 0.83 | TAS1R3 (0.40) | TAS1R3TAS1R1FOLH1BIRC2 | |
| SCHEMBL3182915 | 0.83 | TAS1R3 (0.40) | TAS1R3TAS1R1FOLH1BIRC2 | |
| SCHEMBL3194820 | 0.82 | CTSK (0.43) | TAS1R3TAS1R1 | |
| SCHEMBL3194826 | 0.82 | CTSK (0.43) | TAS1R3TAS1R1 | |
| SCHEMBL11316551 | 0.78 | ALDH1A1 (0.64) | TAS1R3TAS1R1ALDH1A1FOLH1BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | TAS1R3 4138/4885TAS1R1 4218/4885ALDH1A1 4236/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | TAS1R3 4138/4885TAS1R1 4218/4885ALDH1A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.